COVID-19 and HSCT (Hematopoietic stem cell transplant)

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


HSCT recipients are at increased risk for COVID-19-associated morbidity and mortality. Early treatment of symptomatic SARS-CoV-2 infection is an important means to decreasing risk for severe disease and death. While some HSCT recipients, particularly those who are early post-transplant and severely immunosuppressed, may have diminished response to COVID-19 vaccines, the benefits of vaccination are uncontested. Public health, healthcare facility and individual level approaches are all necessary to mitigate risk for infection in this vulnerable population.

Original languageEnglish (US)
Article number101399
JournalBest Practice and Research: Clinical Haematology
Issue number3
StatePublished - Sep 2022


  • COVID-19
  • HSCT
  • Hematopoietic stem cell transplant
  • Prevention
  • SARS-CoV-2
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry


Dive into the research topics of 'COVID-19 and HSCT (Hematopoietic stem cell transplant)'. Together they form a unique fingerprint.

Cite this